NCT01509404 - Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2015

Conditions

Cytomegalovirus Disease

Interventions

DRUG

Valganciclovir

Valcyte per package insert guidelines for 200 days post transplant

BIOLOGICAL

CMV hyperimmune globulin

100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant

DRUG

Valganciclovir

valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant

Trial Locations (1)

Medical University of South Carolina, Charleston